British Patient Capital
Emma Johnson has a diverse work experience in the field of investment management and board membership.
Emma currently holds the position of Senior Investment Manager (Life Sciences) at British Patient Capital, starting in April 2023. Prior to that, they were an Investment Manager (Life Sciences) at the same company from September 2021 to April 2023.
Emma also serves as a Board Member at Epsilogen Ltd, Nucleome Therapeutics, and Grey Wolf Therapeutics, starting in March 2022, October 2022, and December 2022, respectively. Emma is also a Board Observer at Proximie since April 2022.
In addition to their roles in investment management and board membership, Emma was a Steering Committee Member at Fund Their North from June 2020 onwards.
Earlier in their career, Emma worked as an Investment Associate and Investment Analyst at Catapult Ventures Group from February 2020 to September 2021 and from October 2018 to February 2020, respectively. Emma also interned at Catapult Ventures Group as a Life Science Intern in August 2017.
Furthermore, Emma has experience as an Intern at Consulting at McCann Health from June 2017 to July 2017.
Lastly, Emma was a Mind The Brain 2018 Committee Member at the Institute of Cognitive Neuroscience, UCL from January 2018 to May 2018. This role involved organizing a student-led event showcasing research in Cognitive Neuroscience.
Emma Johnson completed their education at the following institutions:
1. UCL: In the years 2017-2018, Emma pursued a Master of Science (MS) degree in Cognitive Neuroscience.
2. University of Bristol: From 2014 to 2017, Emma obtained a Bachelor of Science (BSc) degree in Neuroscience.
3. Upton-by-Chester High School, Chester: Emma attended high school from 2007 to 2014, but no specific degree or field of study is mentioned.
This person is not in any offices
British Patient Capital
British Patient Capital invests in a diversified portfolio of best-in-class venture and growth capital funds and start ups, capturing value through financing the growth of innovative companies. We invest on a commercial basis to deliver competitive returns and manage risk.As well as providing our own funding we work to encourage more investors tomake allocations to this asset class by demonstrating that a long-term patient capital investment strategy can produce commercially attractive returns.Once we’ve established a strong record, and have proved the value of the asset class, we intend to privatise British Patient Capital at an appropriate time in the future.